期刊文献+

盐酸多巴酚丁胺或左西孟旦治疗急性心力衰竭的临床效果及对血清脑利钠肽、尿酸的影响观察 被引量:22

Curative Effect of Dobutamine Hydrochloride or Levosimendan on Acute Heart Failure and Their Influences on Serum Brain Natriuretic Peptide and Uric Acid
下载PDF
导出
摘要 目的探讨盐酸多巴酚丁胺或左西孟旦治疗急性心力衰竭(acute heart failure,AHF)的临床效果及对血清脑利钠肽(brain natriuretic peptide,BNP)、尿酸的影响。方法选取2017年5月—2019年5月收治的78例AHF作为研究对象,根据治疗方法的不同,分为盐酸多巴酚丁胺组和左西孟旦组,每组各39例。盐酸多巴酚丁胺组予盐酸多巴酚丁胺治疗,左西孟旦组予左西孟旦治疗。两组均治疗7 d。观察治疗后临床效果,检测治疗前后心功能相关指标[左心室射血分数(left ventricular ejection fraction,LVEF)、左心室收缩末期容积(left ventricular end-systolic volume,LVESV)、左心室舒张末期容积(left ventricular end-diastolic volume,LVEDV)及每搏输出量(stroke volume,SV)]、BNP、血清炎性因子相关指标[白细胞介素-6(interleukin-6,IL-6)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)]、尿酸及血清K+、Na+水平变化,记录治疗期间不良反应发生情况。结果与盐酸多巴酚丁胺组比较,左西孟旦组治疗后总有效率升高,差异有统计学意义(P<0.05)。与盐酸多巴酚丁胺组治疗后比较,左西孟旦组治疗后LVEF、SV水平升高,血清BNP、IL-6、TNF-α、尿酸水平下降,差异有统计学意义(P<0.05或P<0.01);与本组治疗前比较,两组治疗后LVEF、SV水平升高,LVESV、LVEDV水平降低,血清BNP、IL-6、TNF-α、尿酸水平下降,差异有统计学意义(P<0.05或P<0.01)。治疗期间,两组不良反应总发生率比较差异无统计学意义(P>0.05)。结论左西孟旦较盐酸多巴酚丁胺治疗AHF的临床效果好,有利于降低BNP及尿酸水平,且安全性较高。 Objective To investigate the curative effect of Dobutamine Hydrochloride or Levosimendan on acute heart failure(AHF)and their influences on serum brain natriuretic peptide(BNP)and uric acid(UA).Methods Seventy-eight AHF patients who were admitted from May 2017 and May 2019 were selected as research subjects.They were divided into Dobutamine Hydrochloride group and Levosimendan group according to different treatment methods,with 39 cases in each group.Dobutamine Hydrochloride group was given Dobutamine Hydrochloride,while Levosimendan group was given Levosimendan.All patients were continuously treated for 7 d.The clinical effect was observed,and cardiac function-related indexes[left ventricular ejection fraction(LVEF),left ventricular end-systolic volume(LVESV),left ventricular end-diastolic volume(LVEDV),stroke volume(SV)],BNP and levels of inflammatory factors[(interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)],UA,K+and Na+concentrations were observed.The occurrence of adverse reactions during treatment was recorded.Results After treatment,the total effective rate in Levosimendan group was significantly higher than that in Dobutamine Hydrochloride group(P<0.05).After treatment,the LVEF and SV levels in the Levosimendan group was significantly higher than that of the Dobutamine Hydrochloride group,while the levels of BNP,IL-6,TNF-αand UA were significantly lower than those of the Dobutamine Hydrochloride group(P<0.05 or P<0.01).Compared with those in the same group before treatment,LVEF and SV levels were increased,while LVESV and LVEDV levels,serum BNP,IL-6,TNF-α,and UA levels were decreased after treatment in the two groups.There were significant differences(P<0.05 or P<0.01).There was no difference in the incidence of adverse reactions during treatment between the two groups(P>0.05).Conclusion The curative effect of Levosimendan on AHF is better than that of Dobutamine Hydrochloride,which is more conductive to reduce levels of BNP and UA,with relatively higher safety.
作者 朱洪新 王皓 霍建凤 王涛 ZHU Hong-xin;WANG Hao;HUO Jian-feng;WANG Tao(Department of Cardiology,the Second Hospital of Qinhuangdao,Qinhuangdao,Hebei 066600,China;Department of Respiratory Medicine,the Second Hospital of Qinhuangdao,Qinhuangdao,Hebei 066600,China)
出处 《临床误诊误治》 2020年第9期24-28,共5页 Clinical Misdiagnosis & Mistherapy
基金 秦皇岛市科学技术研究与发展计划(201805A121)。
关键词 心力衰竭 急性 左西孟旦 多巴酚丁胺 利钠肽 尿酸 左心室射血分数 白细胞介素-6 肿瘤坏死因子-α Heart failure,acute Levosimendan Dobutamine Natriuretic peptide,brain Uric acid Left ventricular ejection fraction Interleukin-6 Tumor necrosis factor-alpha
  • 相关文献

参考文献19

二级参考文献139

  • 1刘彤,李立丰,李广平.左西孟旦在急性失代偿心力衰竭治疗中的应用进展[J].中华急诊医学杂志,2006,15(6):571-573. 被引量:6
  • 2郭军,盖鲁粤,杨庭树,刘宏斌,王禹,陈练.危重急性心肌梗死患者住院死亡的危险因素分析[J].内科急危重症杂志,2007,13(4):125-127. 被引量:10
  • 3Ang DS, Wei L, Kao MP, et al. A comparison between Btype natriuretic peptide,global registry of acute coronary events(GRACE) score and their combination in ACS risk stratification [J].Heart, 2009,95(22):1836-1842.
  • 4Vanderheyden M, Vfints C, Verstreken S, et al. B-type natfiuretic peptide as a marker of heart failure:new insights from biochemistry and clinical implication[J].Biomark Med,2010,4(2):315-320.
  • 5方明星,董士民.左西孟旦对脓毒性休克患者血流动力学及心功能的影响[J].中华危重病急救医学,2014,6(10):692-696.
  • 6Leyva F,Anker S,Swan JW,et al.Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure[J].Eur Heart J,1997;18(7):858-65.
  • 7Leyva F,Chua TP,Anker SD,et al.Uric acid in chronic heart failure:a measure of the anaerobic threshold[J].Metabolism,1998;47(9):1156-9.
  • 8Bettencourt P,Ferreira A,Dias P,et al.Predictors of prognosis in patients with stable mild to moderate heart failure[J].J Cardiol Fail,2006;6(4):306-13.
  • 9Martinez A,Gonzalez A,Cerda C,et al.Prognostic value of hyperuricemiain chronic heart failure[J].Rev Med Chil,2004;132(90):1031-6.
  • 10Lankowska EA,Ponikowska B,Majda J,et al.Hyperuricaemia predictspoor outcome in patients with mild to moderate chronic heart failure[J].Int J Cardiol,2007;115(2):151-5.

共引文献550

同被引文献206

引证文献22

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部